Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda CEO Says Orzeyful Could Redefine NT1 Standard of Care
Takeda Pharmaceutical’s first-in-class orexin agonist Orzeyful (oveporexton) will “redefine the standard of care” in narcolepsy type 1 (NT1), CEO Julie Kim said on July 30, a week after the company announced the drug’s world-first approval in China. Speaking at an…
To read the full story
Related Article
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- Takeda’s Oveporexton, Rhythm’s Imcivree Up for Japan Panel Review Aug. 3
July 21, 2026
- Takeda Turns the Page to Kim’s “10-Year” Era, Betting on New Drugs and AI
June 26, 2026
- Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 24, 2026
- Takeda’s Narcolepsy Drug Accepted for US FDA Review
February 12, 2026
BUSINESS
- Chugai Licenses RAF-MEK Molecular Glue to InxMed
September 30, 2026
- OB-GYN Chief Hopes for April 2027 NIP Addition of RSV Antibodies
September 30, 2026
- KM Biologics Eyes Plasma Product Capacity Expansion with Govt Backing
September 30, 2026
- Japan Needs to Boost COVID Vaccine Uptake, Expert Says
September 30, 2026
- Toho, Reprocell Tie Up on Cell Therapy Distribution in Japan
September 30, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…